Oncology pharmacy Onco360 said on Friday that it has signed a specialty pharmacy network partnership with Celgene for its Inrebic product.
Under the specialty pharmacy network partnership, Onco360 has been selected as a specialty pharmacy provider for for Celgene's new product Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).
MF is a serious and rare bone marrow disorder that disrupts the body's normal production of blood cells. Bone marrow is gradually replaced with fibrous scar tissue, which limits the bone marrow to make red blood cells, leading to anemia, fatigue among other symptoms.
Based on Celgene's randomized, Phase III JAKARTA trial, the Inrebic administration resulted in significantly improved MF-associated symptom burden (40% vs 9%) and significantly improved spleen response rates (37% vs 1%) compared to a placebo.
In conjunction, Inrebic is manufactured by Celgene and was approved by the US FDA on 16 August 2019.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial